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Abstract. Brain-derived neurotrophic factor (BDNF) is a 
member of the neurotrophin superfamily which has been 
indicated in the pathophysiology of the nervous system and 
is important in a number of neurological and psychological 
conditions. Recently, BDNF was also shown to play a role in 
the development and progression of solid tumour myeloma. It 
has been reported that BDNF is aberrantly expressed in human 
breast cancer and that a raised level of BDNF is associated with 
poor clinical outcome and reduced survival. The present study 
investigated the role of BDNF in human breast cancer. A panel 
of human breast cancer cells was used and the expression profile 
of BDNF was evaluated using RT-PCR. We constructed a set 
of anti-BDNF transgenes which were used to transfect breast 
cancer cells in order to generate BDNF knocked down cells. 
The impact of BDNF knockdown on growth and apoptosis 
was evaluated. Statistical analysis was performed using SPSS. 
P<0.05 was considered statistically significant. BDNF gene tran-
scripts were successfully detected in the breast cancer cell lines 
MCF-7, MDA-MB-231 and ZR75-1 MDA-MB-231 and MCF-7 
wild-type cells were subject to transfection of anti-BDNF trans-
genes, followed by the establishment of BDNF knocked down 
sublines. Knockdown of BDNF in MDA-MB-231 and MCF-7 
cell lines resulted in decreased rates of growth and proliferation. 
Analysis of apoptosis showed that cell apoptosis was increased 
in cells stably transfected with ribozymes for BDNF compared 
with the vector control. It is concluded that BDNF, a neuro-
trophic growth factor aberrantly expressed in cancers such as 
breast cancer, has a profound impact on the cellular behaviour of 
breast cancer cells and that BDNF is associated with a reduction 
of the apoptosis of breast cancer. BDNF is, therefore, a potential 
therapeutic target in breast cancer and its effect in human breast 
cancer requires further investigation.
Introduction
The incidence of breast cancer continues to rise. Breast cancer 
is one of the common carcinoma in women. The treatment of 
breast cancer includes routine surgery, radiotherapy, biotherapy 
and hormone therapy. These treatments have shortcomings due 
to side effects and lack of response due to the different genetic 
makeup of the individual and their disposition to breast cancer. 
Recently, there has been a move towards an individual treatment 
regime. The search therefore continues to find markers and/
or targets for therapy (1,2). Brain-derived neurotrophic factor, 
BDNF is a member of the neurotrophins superfamily composed 
of 247 amino acids which has separated and purified from pig 
brain (3). BDNF activates cellular biological effects mainly 
through a cell surface tyrosine kinase receptor, tropo-myosin-
related kinase B (TrkB). It has been reported that brain-derived 
neurotrophic factor (BDNF) is aberrantly expressed in human 
breast cancer and that a raised level of BDNF is associated 
with poor clinical outcome and reduced survival (4,5). BDNF 
is secreted by target non-neuronal cells of neuron and has been 
implicated in the pathophysiology of the nervous system and is 
important in a number of neurological and psychological condi-
tions (6,7).
Recently, in addition to BDNF involvement in the nerve 
system carcinomas, it has also been shown to play a role in the 
proliferation, invasion and metastasis of non-neuronal solid 
tumours such as breast cancer, myeloma, melanoma, lung 
cancer, ovarian cancer, hepatocellular and prostate cancer 
(5,8-11). The expression level of BDNF is also of high concern 
in cancer research (12).
Nerve growth factor (NGF) and BDNF have similar primary 
structures and relative functions which stimulate neuron cell 
survival, differentiation and neuroplasticity (6). NGF has been 
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found incorporated to promote survival and proliferation of 
breast cancer cells which has been used in hormone therapy 
of breast cancer (5). The impact of expression level of BDNF 
on breast cancers especially diminishing the expression level 
would be helpful to the treatment of the breast cancer.
The present study aimed to investigate the biological 
role of BDNF expression in human breast cancer cells. We 
found high expression of BDNF in MDA-MB-231, MCF-7 
and ZR75-1 breast cancer cells and so anti-BDNF ribozymes 
were constructed to knock down the expression of BDNF in 
MDA-MB-231 and MCF-7 cells. The expression profile of 
BDNF was evaluated and screened, then the biological influ-
ence was studied in breast cancer cells.
Materials and methods
Cell lines and culture. Human breast cell lines, MDA-MB-
231, MCF-7 and ZR75-1 were obtained from the European 
Collection of Animal Cell Cultures (ECACC, Salisbury, UK). 
Cells were maintained in Dulbecco's modified Eagle's medium 
(DMEM) containing 10% fetal calf serum, 100 U/ml penicillin 
and 100 µg/ml streptomycin (Gibco BRC, Paisley, UK) at 37˚C 
and 5% CO2.
RNA preparation and reverse transcription PCR (RT-PCR). 
Total cellular RNA was extacted from the cultured cells 
using Total RNA Isolation reagent (ABgene, Epsom, UK). 
The concentration of RNA was determined through an ultra-
violet spectrophotometer (WPA UV 1101, Biotech Photometer, 
Cambridge, UK). cDNA was obtained from RT-PCR using a 
transcription kit (Sigma, Poole, UK). The quality of DNA was 
verified using GAPDH primers (forward primer: 5'-AGC TTG 
TCA TCA ATG GAA AT-3'; reverse primer: 5'-CTT CAC 
CAC CTT CTT GAT GT-3'). The mRNA level of BDNF were 
assessed using the BDNF primers (forward primer: 5'-TTC ATA 
CTT TGG TTG CAT GA-3'; reverse primer: 5'-TTC AGT TGG 
CCT TTT GAT AC-3'). PCR were running in a GeneAmp PCR 
System 2400 thermocycler (Perkin-Elmer). The PCR products 
were separated by 1% agarose gel and stained with ethidium 
bromide then photographed by a digital camera mounted over a 
UV transilluminator.
Real-time quantitative polymerase chain reaction. The mRNA 
level of gene expression was determined by the real-time 
quantitative polymerase chain reaction (QPCR) method using 
the prepared cDNA as the template. An additional primer 
sequence was added to every QPCR reaction system, known as 
the Z sequence (5'-ACT GAA CCT GAC CGT ACA-3') which 
is complementary to the universal Z probe (Intergen Inc., 
Oxford, UK). The reaction was carried out on IcyclerIQ™ 
(Bio-Rad, Hemel Hemstead, UK) in real-time detection of 
the 96-well plate. GAPDH expression was used as an internal 
control. The reaction condition was: 94˚C for 7 min, 80 cycles 
of 94˚C for 15 sec, 55˚C for 35 sec (the data capture step) and 
72˚C for 20 sec. The levels of the transcripts were generated 
from an internal standard that was simultaneously amplified 
with the samples.
Knockdown of BDNF expression using ribozyme and screen of 
stable transfected cell lines. Targeting human BDNF hammer-
head ribozymes were designed based on the secondary structure 
of the gene generated using the Zuker RNA mFold program. 
The ribozymes were accordingly synthesized and then cloned 
into pEF6/V5-his-Topo T/A vector (Invitrogen, Paisley, UK). 
Then transfected to MDA-MB-231 and MCF-7 cells respectively 
using an Easyjet Plus electroporator (EquiBio, Kent, UK). After 
selection with culture medium containing 5 µg/ml blasticidin, 
the verified transfectants were cultured in medium containing 
0.5 µg/ml blasticidin. Primer sequences of the anti-BDNF 
ribozymes were: forward primer: 5'-CTG CAG TTG GCC TTT 
TGA TAC AGG GAC CTT TTC AAG GAC TGT CTG ATG 
AGT CCG TGA GGA-3'; reverse primer: 5'-CTG CAG TTG 
GCC TTT TGA TAC AGG GAC CTT TTC AAG GAC TGT 
CTG ATG AGT CCG TGA GGA-3'.
Western blotting experiment. Human breast cancer cells were 
collected and lysed in lysate buffer. The protein concentration 
was quantified using DC Protein Assay kit (Bio-Rad) and an 
ELx800 spectrophotometer (Bio-Tek). Lysates were detected 
by SDS-PAGE and western blot analysis. The transferred 
membranes were incubated with the primary antiby anti-BDNF 
and anti-TrkB antibody (Santa Cruz Biotechnologies, Santa 
Cruz, CA, USA). GAPDH expression was used as an internal 
control (Santa Cruz Biotechnologies). Then incubated with the 
peroxidase-conjugated secondary antibody (Sigma-Aldrich). 
Western blotting results were detected by chemiluminescence 
and visualized using a Supersignal West Dura system (Pierce 
Biotechnology, Inc.) and photographed using a UVI-Tech imager 
(Uvitech, Cambridge, UK). Protein level were quantified and 
analyzed with NIH Image 1.62.
Cell growth assay. Breast cancer cell growth rates were assessed 
using an in vitro growth assay. Cells were planted in sextuplicate 
into 96-well plates at a density of 2,000 cells per well. Plates 
were then incubated for 24, 48, 72 and 120 h before being fixed in 
4% formaldehyde (v/v) and stained with 0.5% (w/v) crystal violet. 
The crystal violet stain was then dissolved using 10% acetic 
acid (v/v) and cell density was determined by measuring the 
absorbance of this solution at 540 nm using a Bio-Tek ELx800 
multi-plate reader (Bio-Tek Instruments Inc., Winooski, VT).
Flow cytometric analysis of apoptosis. All cells including those 
floating in the culture medium were harvested after incubation. 
Cells were washed in cold BSS and resuspended in 1X annexin 
V-binding buffer at a density of 1x106 cells/ml after centrifuga-
tion. FITC annexin V (5 µl) and 1 µl of the PI working solution 
(100 µg/ml) (Molecular Probes, OR, USA) were added to 
100 µl the cell suspension. After a 15-min incubation at room 
temperature, 400 µl of 1X annexin V-binding buffer was added, 
mixed gently and the samples were immediately placed on ice. 
The stained cells were analyzed using the flow cytometer and 
FlowMax software.
Statistical analysis. Statistical analysis was performed using 
SPSS. P<0.05 was considered statistically significant.
Results
mRNA expression of BDNF in human breast cancer cell lines. 
Human cancer cell lines MDA-MB-231, MCF-7 and ZR-751 
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were examined for the presence of BDNF using RT-PCR (Fig. 1). 
BDNF was strongly expressed in all three cell lines. Fetal kidney 
tissue was used as a positive control. The negative control had no 
DNA template (data not shown).
BDNF knockdown and establishment of stable cell lines. The 
ribozymes targeting BDNF were cloned into pEF6/V5-his-Topo 
T/A vector. MDA-MB-231 and MCF-7 wild-type cells were 
subjected to transfection using plasmids containing ribozymes 
targeting BDNF or an empty vector control, respectively, 
followed by the establishment of BDNF knockdown sub-lines 
and empty vector (pEF) control cells. The expression of BDNF 
at the mRNA level was reduced in both BDNF knocked down 
MDA-MB-231 and MCF-7 cells using RT-PCR and QPCR. 
(Fig. 2A and B). The protein levels were also decreased in BDNF 
knocked down MDA-MB-231 cells using western blotting 
(Fig. 2C). We then characterized the effect of BDNF knockdown 
in these cells through a series of in vitro studies.
Effects of BDNF knockdown on the growth of human breast 
cancer cells. In the in vitro growth assay, knockdown of BDNF 
in MDA-MB-231 cells resulted in a reduction of cell growth 
rate (growth rate in BDNF knocked down MDA-MB-231 cells 
by day 3 was 3.55±0.69, compared with 7.47±0.65 in pEF, 
p<0.001). Loss of BDNF in MCF-7 cells resulted in reduction of 
cell growth rate (growth rate in BDNF knocked-down MCF-7 
cells by day 3 was 2.59±0.58, compared with 3.45±0.07 in pEF, 
p=0.012) (Fig. 3A). These data demonstrate that BDNF may 
increase breast cancer cell growth.
To confirm this effect, a rescue assay was performed with 
the addition of BDNF protein to the cell culture medium (50 ng/
ml) (Abcam, Cambridge, UK). As a result, the reduced growth 
rate in the knockdown cells was attenuated (Fig. 3B). These 
data indicated that BDNF is involved in increased cell growth.
Figure 1. BDNF is expressed in human breast cancer cell lines. Detection of 
BDNF mRNA transcript in MCF-7, MDA-MB-231 and ZR751 breast cancer 
cell lines using RT-PCR. GAPDH was used as housekeeping control.
Figure 2. Knock down of BDNF expression in MDA-MB-231 and MCF-7 cell 
lines. (A) RT-PCR showed BDNF knockdown at the mRNA level in MDA-
MB-231 and MCF-7 cell lines. (B) QPCR showed BDNF knockdown at the 
mRNA level in MDA-MB-231 and MCF-7 cell lines. (C) Western blotting 
showed BDNF knockdown at the mRNA level in MDA-MB-231 cell lines.
Figure 3. Effects of BDNF knockdown on cell growth. (A) Knockdown 
BDNF inhibited MDA-MB-231 cell growth compared with the vector control. 
(B) Knockdown BDNF inhibited MDA-MB-231 cell growth compared with 
the vector control. (C) Knockdown BDNF inhibited MDA-MB-231 cell growth 
was abolished by culture medium containing BDNF (50 ng/ml) compared with 
the vector control.
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Effects of BDNF knocked-down on cell apoptosis. To investigate 
whether apoptosis is involved in the effect of BDNF knocked 
down in MDA-MB-231 and MCF-7 cells, we determined the 
proportion of apoptotic cells. As shown in Fig. 4A-D, there was 
an increase in cell population towards apoptosis in the BDNF 
knocked down MDA-MB-231 cells, which was 6.01% in the 
BDNF knocked down cells, compared with 4.05% in the pEF 
control. There was also an increase of apoptosis in the BDNF 
Figure 4. Effects of BDNF knockdown on cell apoptosis. (A) BDNF knockdown induced apoptosis in MDA-MB-231 cell lines. (B) BDNF knockdown induced 
apoptosis in MCF-7 cell lines. (C and D) Statistics for both (A) and (B). (E) The apoptotic population in MDA-MB-231 cell lines were analyzed using flow 
cytometry after exposure to BDNF (50 ng/ml) for 48 h. Apoptosis was reduced compared with vector control. (F) Statistics.
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knocked down MCF-7 cells, which was 10.88% in the BDNF 
knocked down cells, compared with 7.66% in the pEF control. 
This result suggests that BDNF decreases apoptosis in these 
cells.
Moreover, we confirmed whether or not this effect was 
specific to BDNF knockdown by rescue experiments. BDNF 
protein was added in the cell culture medium (50 ng/ml) and 
resulted in negative effect of BDNF knockdown compared to 
the pEF controls (Fig. 4E and F).
Effects of BDNF knockdown on cellular signal pathways. We 
screened the cells at the mRNA transcript level for p53 and 
NFκB in BDNF knocked down MDA-MB-231 cells using 
QPCR. The results showed that the level of p53 was decreased in 
BDNF knock down MDA-MB-231 and MCF-7 cells, indicating 
that BDNF stimulates the message for p53. mRNA levels of the 
NFκB was increased in BDNF knock down MDA-MB-231 and 
MCF-7 cells, indicating that BDNF affects the level of NFκB. 
From these results, we can infer that BDNF increases apoptosis 
through decreasing the anti-apoptosis factor NFκB and increase 
p53 (Fig. 5A and C).
Further, we examined the serine phosphorylation status of 
AKT in MDA-MB-231 knocked down cells. We found that the 
phosphorylation level of AKT was weak in BDNF knocked-
down cells (Fig. 5B).
Discussion
BDNF has been described as a cancer related factor involved in 
breast cancer cell growth with a correlation to survival relevance 
in patients with breast cancer. However, the biological function 
of BDNF and the many cellular molecular pathways induced by 
BDNF are unknown (4).
The expression of BDNF and TrkB mRNA has been found 
to be higher in human cancer cell lines than in normal tissues 
(8). Our results also show mRNA expression level of BDNF 
in human breast cancer to be elevated and so we utilised 
RNA knockdown to study the influence of BDNF expression 
on cellular function and possible molecular mechanisms. In 
the present study we obtained stable knockdown of BDNF in 
human breast cancer cell lines using BDNF ribozymes.
When BDNF was stably knocked down in MDA-MB-231 
and MCF-7 cell lines, the growth decreased compared with 
the vector control, suggesting that reduced BDNF gene expres-
sion could inhibit cellular proliferation. Cell proliferation was 
restored when stimulated by BDNF protein. BDNF is therefore 
involved in proliferation regulation of human breast cancer cell 
proliferation.
The apoptosis experiments demonstrated that in those 
MDA-MB-231 and MCF-7 cell lines in which BDNF was stably 
knocked down, apoptosis increased compared with the vector 
control. This suggests that BDNF is a regulator of apoptosis in 
these cells. It can be concluded that BDNF can maintain breast 
cancer cell survival and proliferation.
The influence of BDNF on cellular biological function is 
induced mainly by its receptor TrkB. When BDNF binds to 
TrkB the tyrosine kinase activity of the receptor is activated via 
phosphorylation of tyrosine residues in the cytoplasmic region 
of the receptor which in turn induces cellular signaling (13). The 
PI3K-AKT pathway is highly related to cell survival and PI3K 
has been shown to play a key role in anti-apoptotic survival 
and proliferation (14-16). We have found that phosphorylation 
of the AKT signal was weak in BDNF knocked down cells 
compared with vector control when treatment with BDNF. This 
result show that BDNF activates the AKT pathway in order to 
maintain cell survival (10). The MAPK pathway is known to be 
involved in proliferation but we did not find obvious changes in 
ERK1/2 phosphorylation in BDNF knocked down cells.
In this study, we also investigated the expression of down-
stream molecules related to the AKT pathway. The nuclear 
transcription factor, NFκB was found to be downregulation 
in the BDNF knocked down MDA-MB-231 cells but Bcl-2 
demostrated no obvious changes (data not shown) compared 
with vector control. Therefore, the NFκB expression inhibi-
tion induced by BDNF downregulation may inhibit nucleolar 
transcription as a trigger for cell apoptosis (17). Accordingly, 
BDNF can facilitate NFκB expression to induce cell prolif-
eration.
Figure 5. Effects of BDNF knockdown on the cellular signal pathway. (A) BDNF 
knockdown reduced the mRNA expression level of NFκB as shown by RT-PCR. 
(B) BDNF knockdown reduced the phosphorylation of AKT as shown using 
western blotting. (C) BDNF knockdown reduced the mRNA expression level 
of p53.
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We found that the mRNA transcription level of p53 was 
elevated in BDNF knocked down MDA-MB-231 cells compared 
with vector control. p53 is well-known to be a pro-apoptotic 
protein related to cell survival. p53 trancription increase induced 
by lower BDNF expression may increase cell apoptosis. BDNF 
has been found to mediate protection from apoptosis by p53 acti-
vation (18). High expression of BDNF and its receptor TrkB have 
been found in cancers related to metastasis and poor prognosis, 
in addition p53 is related in the late process of tumor progression 
and predict of a poor prognosis in squamous cell carcinoma of 
the uterine cervix (4,19).
The BDNF downregulation induced abolishment of protec-
tion from apoptosis is affected by triggering downstream 
interplay between NFκB activation and p53 inhibition. This 
abolishment is not effected by upregulation of the BDNF-
Akt-Bcl2 anti-apoptotic signaling pathway (15).
In conclusion, our study showed that BDNF facilitated cell 
proliferation and inhibited cell apoptosis in human breast cancer 
cells. Reduced BDNF expression induces changes in down-
stream signaling molecules, which are related to cell survival 
and apoptosis. BDNF is therefore a potential therapeutic target 
in breast cancer and its effect in human breast cancer requires 
further investigation.
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